Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-09-06 Capital/Financing Update
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a collaboration between Lupin Limited, Mark Cuban Cost Plus Drug Company, and the COPD Foundation to expand access to medication for COPD patients. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which governs material event disclosures by listed companies. The content focuses on a business collaboration and product availability, not on financial results, management changes, or regulatory filings. The document is about a corporate announcement rather than a financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which includes updates on company activities related to business collaborations and strategic partnerships that impact the company's operations and market position.
2023-09-06 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) disclosing an acquisition transaction pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements. It informs about the completion of an acquisition by a wholly owned subsidiary, including payment details and regulatory approval. The document is short (2324 characters) and serves as a disclosure announcement rather than a detailed financial report or filing. It does not contain financial statements, audit information, or detailed management discussion. It is an update on a capital transaction (acquisition) and fits best under Capital/Financing Update (CAP).
2023-09-01 English
Completion of acquisition of entire share capital of French Pharmaceutical Company Medisol, consequent upon receipt of approval from the French Ministry of Economy and Finance.
Regulatory Filings
2023-09-01 English
Lupin launches Propranolol Long-Acting Capsules to improve Heart Heath in Canda.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Propranolol long-acting capsules) in Canada by Lupin Limited. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content focuses on product launch information and corporate communication rather than financial results, management changes, or regulatory filings. The document length is about 5105 characters, which is relatively short and typical for a press release. There is no detailed financial data, no audit information, no voting results, no legal proceedings, no earnings data, and no investor presentation content. Therefore, the document fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement or disclosure under listing obligations, rather than a financial report or other specific filing type.
2023-08-29 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Propranolol long-acting capsules) in Canada by Lupin Limited. It is addressed to stock exchanges (BSE and NSE) and references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content focuses on product launch information and corporate communication rather than financial results, management changes, or regulatory filings. The document length is about 5105 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, no voting results, no audit information, or other regulatory filings. Therefore, this document fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement or disclosure pursuant to listing obligations, which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-08-29 English
Lupin receives approval from U.S. FDA for Pirfenidone Capsules.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which governs material event disclosures. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is under 5,000 characters and it is a standalone announcement without financial data or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2023-08-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.